文献速递外周动脉疾病

专用系统经皮深静脉动脉化治疗无选择慢性肢体威胁性缺血患者的中期结果:ALPS多中心研究

Midterm Outcomes of Percutaneous Deep Venous Arterialization With a Dedicated System for Patients With No-Option Chronic Limb-Threatening Ischemia: The ALPS Multicenter Study.
PubMed 文献 · J Endovasc Ther · 2020-05-18

技术成功率达96.9%,6、12、24个月的无截肢生存率分别为83.9%、71.0%、67.2%,保肢率分别为86.8%、79.8%、79.8%,完全伤口愈合率分别为36.6%、68.2%、72.7%。pDVA在此复杂患者群中可行,可能成为预防截肢和促进伤口愈合的推荐治疗。

要点

  • pDVA技术成功率高(96.9%),中期无截肢生存率和保肢率可接受。
  • 完全伤口愈合率随时间提高,中位愈合时间4.9个月。
  • DVA环路闭塞常见(21例),中位闭塞时间2.6个月,多数需再干预。

核心结论

  • 在无选择CLTI患者中,使用Limflow装置的pDVA可行,技术成功率高,6至24个月的无截肢生存率结合伤口愈合情况良好。
  • 对于经选择的无法选择CLTI患者,pDVA可作为预防截肢和促进伤口愈合的推荐治疗。

研究设计与样本

  • 主要结局为6个月无截肢生存率(AFS);次要结局为6、12、24个月的伤口愈合、保肢和生存。

主要发现

  • 技术成功31例(96.9%),中位随访34个月(范围16-63)。
  • 6、12、24个月AFS估计值分别为83.9%、71.0%、67.2%。
  • 6、12、24个月保肢率估计值分别为86.8%、79.8%、79.8%。
  • 6、12、24个月完全伤口愈合率估计值分别为36.6%、68.2%、72.7%。
  • 完全伤口愈合中位时间4.9个月(范围0.5-15),随访期间21例DVA环路闭塞,中位闭塞时间2.6个月,17例因闭塞再干预(16例因未愈合伤口,1例因新发溃疡)。

临床怎么用

  • 对于无选择CLTI患者,可考虑使用Limflow装置行pDVA以预防截肢和促进伤口愈合。
  • 术后需密切监测DVA环路闭塞,必要时再干预以促进伤口愈合。

局限性

  • 缺乏对照组,随访时间范围较大(16-63个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: To evaluate the midterm results of patients suffering from no-option chronic limb-threatening ischemia (CLTI) treated with a dedicated system for percutaneous deep venous arterialization (pDVA). Materials and Methods: Thirty-two consecutive CLTI patients (mean age 67±14 years; 20 men) treated with pDVA using the Limflow device at 4 centers between 11 July 2014 and 11 June 2018 were retrospectively analyzed. Of all patients, 21 (66%) had diabetes, 8 (25%) were on immunosuppression, 4 (16%) had dialysis-dependent renal failure, 9 (28%) had Rutherford category 6 ischemia, and 25 (78%) were deemed at high risk of amputation. The primary outcome was amputation-free survival (AFS) at 6 months. Secondary outcomes were wound healing, limb salvage, and survival at 6, 12, and 24 months. Results: Technical success was achieved in 31 patients (96.9%). The median follow-up was 34 months (range 16-63). At 6, 12, and 24 months, estimates were 83.9%, 71.0%, and 67.2% for AFS, 86.8%, 79.8% and 79.8% for limb salvage, and 36.6%, 68.2%, and 72.7% for complete wound healing, respectively. Median time to complete wound healing was 4.9 months (range 0.5-15). The DVA circuit occluded during follow-up in 21 patients; the median time to occlusion was 2.6 months. Reintervention for occlusion was performed in 17 patients: 16 because of unhealed wounds and 1 for a newly developed ulcer. Conclusion: This study represents the largest population of patients with no-option CLTI treated with pDVA using the LimFlow device with midterm results. In this complex group of patients, pDVA using the LimFlow device has been shown to be feasible, with a high technical success rate and AFS at 6 up to 24 months coupled with wound healing. In selected patients with no-option CLTI, pDVA could be a recommended treatment to prevent amputation and heal wounds.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Schmidt A, Schreve MA, Huizing E, et al. Midterm Outcomes of Percutaneous Deep Venous Arterialization With a Dedicated System for Patients With No-Option Chronic Limb-Threatening Ischemia: The ALPS Multicenter Study. J Endovasc Ther. 2020. PMID: 32419597. doi:10.1177/1526602820922179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。